NXTC Stock Financial Analysis - NextCure, Inc. (NasdaqGS) Stock

Overview

NextCure, Inc., headquartered in the United States, is a biopharmaceutical company focused mainly on discovering and developing novel immunotherapies that target cancer and other immune-related diseases. Operating within the biotechnology industry, NextCure is pioneering research with its proprietary FIND-IO platform, which systematically profiles molecular interactions to identify new targets involved in immuno-oncology. Among its key projects, the development of NC318, a novel immunomedicine targeting the Siglec-15 immune pathway, stands out as a primary focus. This project, along with others like NC410, which aims to modulate immune response to combat cancer, positions NextCure at the forefront of next-generation cancer therapy innovations. Their strategic approach combines cutting-edge technology and rigorous science to address unmet medical needs in oncology.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for NextCure, Inc. as of June 30, 2025 is -63.86 MM.
The net income for NextCure, Inc. as of June 30, 2025 is -60.93 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-63.86	-60.93
2025-03-31		-53.07	-49.52
2024-12-31		-57.21	-55.65
2024-09-30		-60.54	-58.52
2024-06-30		-63.66	-61.28
2024-03-31		-66.33	-63.73
2023-12-31		-67.64	-62.72
2023-09-30		-69.62	-65.56
2023-06-30		-73.24	-70.17
2023-03-31		-72.21	-70.23
2022-12-31		-75.91	-74.73
2022-09-30		-75.21	-74.37
2022-06-30		-74.48	-73.39
2022-03-31		-74.30	-73.46
2021-12-31		-70.77	-69.39
2021-09-30	0.00	-69.93	-67.91
2021-06-30	0.00	-68.82	-66.35
2021-03-31	0.00	-66.67	-62.87
2020-12-31	22.38	-41.23	-36.60
2020-09-30	24.38	-37.00	-32.07

Income Statement: EPS

The earnings per share basic for NextCure, Inc. as of June 30, 2025 is -26.00.
The earnings per share diluted for NextCure, Inc. as of June 30, 2025 is -26.00.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-26.00	-26.00
2025-03-31	-21.23	-21.23
2024-12-31	-23.88
2024-09-30	-25.13	-25.13
2024-06-30	-26.35	-26.35
2024-03-31	-27.44	-27.44
2023-12-31	-27.04
2023-09-30	-28.29	-28.29
2023-06-30	-30.31	-30.30
2023-03-31	-30.36	-30.40
2022-12-31	-32.32
2022-09-30	-32.21	-32.20
2022-06-30	-31.82	-31.83
2022-03-31	-31.89	-31.85
2021-12-31	-30.15
2021-09-30	-29.53	-29.54
2021-06-30	-28.87	-28.87
2021-03-31	-27.38	-27.36
2020-12-31	-15.95	-15.96
2020-09-30	-14.32	-14.32

Cash Flow: Operations, Investing, Financing

The cash from operating activities for NextCure, Inc. as of June 30, 2025 is -54.13 MM.
The cash from investing activities for NextCure, Inc. as of June 30, 2025 is 36.12 MM.
The cash from financing activities for NextCure, Inc. as of June 30, 2025 is 2.06 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-54.13	36.12	2.06
2025-03-31	-41.19	44.52	0.14
2024-12-31	-40.80	55.31	0.14
2024-09-30	-44.51	52.51	0.18
2024-06-30	-45.83	44.48	0.18
2024-03-31	-50.80	39.03	0.15
2023-12-31	-52.97	39.27	0.15
2023-09-30	-51.25	39.58	0.14
2023-06-30	-53.48	47.19	0.14
2023-03-31	-53.22	72.40	0.14
2022-12-31	-53.89	67.98	0.20
2022-09-30	-58.42	52.51	0.26
2022-06-30	-56.09	49.04	-2.37
2022-03-31	-58.82	32.70	-2.85
2021-12-31	-57.28	36.60	-3.27
2021-09-30	-50.07	64.10	-3.79
2021-06-30	-53.08	62.79	-1.52
2021-03-31	-48.27	55.75	-1.53
2020-12-31	-44.95	43.52	-1.42
2020-09-30	-48.67	-100.14	160.29

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for NextCure, Inc. as of June 30, 2025 is 0.24.
The p/tbv for NextCure, Inc. as of June 30, 2025 is 0.24.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		0.24	0.24
2025-03-31		0.21	0.21
2024-12-31		0.31	0.31
2024-09-30	-0.63	0.45	0.45
2024-06-30	-0.72	0.46	0.46
2024-03-31	-0.86	0.47	0.47
2023-12-31	-0.49	0.25	0.25
2023-09-30	-0.53	0.27	0.27
2023-06-30	-0.65	0.29	0.29
2023-03-31	-0.55	0.25
2022-12-31		0.22	0.22
2022-09-30		0.38	0.38
2022-06-30	-1.78	0.61	0.61
2022-03-31	-1.94	0.58	0.58
2021-12-31	-2.44	0.67	0.67
2021-09-30	-2.80	0.71	0.71
2021-06-30
2021-03-31	-1.87	0.42	0.42
2020-12-31	-3.22	0.40	0.40
2020-09-30	-3.67	0.38	0.38

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for NextCure, Inc. as of June 30, 2025 is 5.72.
The ebit (3y)/ev for NextCure, Inc. as of June 30, 2025 is 6.96.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	5.72	6.96
2025-03-31	4.05	4.60
2024-12-31	13.13	14.66
2024-09-30	-3.45	-3.78
2024-06-30	-2.32	-2.51
2024-03-31	-1.53	-1.69
2023-12-31	-5.33	-5.64
2023-09-30	-4.68	-4.66
2023-06-30	-4.56	-4.55
2023-03-31	-5.16	-4.86
2022-12-31	-8.86	-6.93
2022-09-30	-1.53	-1.21
2022-06-30	-0.61	-0.46
2022-03-31	-0.57	-0.41
2021-12-31	-0.52	-0.35
2021-09-30	-0.43	-0.28
2021-06-30
2021-03-31	-0.74	-0.41
2020-12-31	-0.41	-0.35
2020-09-30	-0.32	-0.21

Management Effectiveness

The roa for NextCure, Inc. as of June 30, 2025 is -0.48.
The roe for NextCure, Inc. as of June 30, 2025 is -0.58.
The roic for NextCure, Inc. as of June 30, 2025 is -0.80.
The croic for NextCure, Inc. as of June 30, 2025 is 0.06.
The ocroic for NextCure, Inc. as of June 30, 2025 is -0.67.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.48	-0.58	-0.80	0.06	-0.67
2025-03-31	-0.48	-0.56	-0.78	0.21	-0.57
2024-12-31	-0.46	-0.51	-0.72	0.10	-0.54
2024-09-30	-0.44	-0.48	-0.67	-0.01	-0.50
2024-06-30	-0.38	-0.41	-0.60	-0.11	-0.48
2024-03-31	-0.34	-0.37	-0.52	-0.11	-0.44
2023-12-31	-0.35	-0.36	-0.49	-0.09	-0.38
2023-09-30	-0.34	-0.35	-0.48	-0.04	-0.37
2023-06-30	-0.34	-0.35	-0.48	-0.04	-0.37
2023-03-31	-0.34	-0.35	-0.44	0.12	-0.33
2022-12-31	-0.29	-0.30	-0.41	-0.03	-0.32
2022-09-30	-0.28	-0.30	-0.41	-0.03	-0.32
2022-06-30	-0.27	-0.28	-0.37	-0.05	-0.28
2022-03-31	-0.24	-0.25	-0.34	-0.14	-0.27
2021-12-31	-0.22	-0.23	-0.29	-0.10	-0.20
2021-09-30	-0.21	-0.22	-0.27	0.04	-0.20
2021-06-30	-0.20	-0.21	-0.25	0.03	-0.20
2021-03-31	-0.18	-0.19	-0.22	0.02	-0.17
2020-12-31	-0.10	-0.11	-0.12	-0.01	-0.15
2020-09-30	-0.16	-0.19	-0.10	0.04	-0.16

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31	-1.08	-1.64	-1.84
2020-09-30	-0.88	-1.32	-1.52